KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Rigel Pharmaceuticals (RIGL) Accumulated Depreciation & Amortization (2016 - 2025)

Rigel Pharmaceuticals has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 8.39% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, up 8.39%, while the annual FY2025 figure was $2.4 million, 8.39% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $2.4 million at Rigel Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $2.4 million in Q4 2025 and troughed at $900000.0 in Q4 2022.
  • A 5-year average of $1.6 million and a median of $1.2 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: dropped 25.0% in 2022 and later soared 79.97% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.2 million in 2021, then dropped by 25.0% to $900000.0 in 2022, then skyrocketed by 37.56% to $1.2 million in 2023, then soared by 79.97% to $2.2 million in 2024, then rose by 8.39% to $2.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for RIGL at $2.4 million in Q4 2025, $2.2 million in Q4 2024, and $1.2 million in Q4 2023.